ImmunoCellular Therapeutics to present at 2nd World Cancer Vaccines Summit

Biotech company ImmunoCellular Therapeutics (OTCBB:IMUC) said Wednesday that its president and CEO, Dr. Manish Singh, will present at the 2nd World Cancer Vaccines Summit in Boston on June 23rd.
The presentation titled, "Multiple Antigen Vaccines for Glioblastoma", will feature ICT-107, the company's vaccine candidate for the treatment of glioblastoma multiforme (GBM), an aggresive type of brain cancer.
The vaccine uses cancer stem cells to target multiple tumour-associated antigens, which generate an antibody response from the body's own immune system.
In other words, white blood cells are primed in the lab to attach to markers present in brain tumours, and these cells are then injected back into the body, where they travel to the brain and attack tumour cells.
In a phase one trial of the vaccine, 80% of 16 patients showed a two-year overall survival rate, while 44% also showed a progression-free survival rate. Even more, six of the 16 clinical patients are now disease-free.
The presentation will describe how the vaccine works, as well as all recent developments, and the multi-centre phase two trial currently underway. The Los Angeles-based company recently announced the expansion of the phase two study from up to 15 clinical centres to 20 or more.
The new study is a double-blind, placebo-controlled test to determine the safety and efficacy of the vaccine in patients with newly diagnosed glioblastoma multiforme.
ImmunoCellular's Summit presentation will be held at Boston's Radisson Hotel at 2:00pm on June 23rd, and will see executives from major oncology pharmaceutical companies, cancer vaccine biotechs and investigators in the field.